Breaking News, Collaborations & Alliances

Mabion, NovalGen Partner to Bring NVG-222 to Market

The companies have released the first batch of Novalgen’s next-generation T-cell engager for first in-human clinical trials.

Author Image

By: Charlie Sternberg

Associate Editor

In order to accelerate the global fight against blood cancers and hard-to-treat solid tumors, end- to-end biologics CDMO Mabion has entered a strategic development and manufacturing partnership with London-based NovalGen to bring the proprietary T-cell engager, NVG-222, to market for phase one of in-human clinical trials which are scheduled to begin in the second half of 2025. NVG-222 is a bispecific T-cell engager targeting ROR1 and CD3 that could be used to treat both blood cancers and soli...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters